Chongqing Zhifei Biological Products Co., Ltd. (“Zhifei” or “the Company” for short) has its presence in biological product industry in 2002. The Company achieved an operating income of RMB13.2 billion  In the first half of 2021  with the support of its nearly 4500 employees based on its registered capital of RMB1.6 billion and total assets of RMB23.9 billion.In September 2010, Zhifei was listed on the Shenzhen Stock Exchange (stock code: 300122), becoming the first privately-run vaccine enterprise listed on ChiNext. Zhifei has five wholly-owned subsidiaries and a joint-stock subsidiary, of which Beijing ZhifeiLvzhu Biopharmaceutical Co., Ltd. and Anhui ZhifeiLongcom Biopharmaceutical Co., Ltd. are new high-tech enterprises.

As a high-tech biological enterprise integrating the R&D, production, marketing, distribution as well as import & export, Zhifei mainly engages in the production of vaccines for human use, which is one of seven strategic emerging industries of China and has a broad development prospect. The commercially available products of the Company include Recombinant Novel Coronavirus Vaccine (CHO Cell)，Recombinant Mycobacterium Tuberculosis Fusion Protein (EC) (Ekear®), Haemophilus Influenzae Type b Vaccine (XiFeiBei®), Group ACYW₁₃₅ Meningococcal Polysaccharide Vaccine (Menwayc®), Mycobacterium Vaccae for Injection (Vaccae®), Meningococcal Group A and Group C Polysaccharide Conjugate Vaccine (Mening A Con®), and other independently developed products. Meantime, Zhifei is the sole distributor of the vaccines of Merck Sharp &Dohme(MSD) such as HPV4(Gradasil),HPV9(Gradasil 9),5-valent rotavirus vaccine(Rotateq),23-valent Pneumonia vaccine(Pneumovax 23),Hepatitis A vaccine(Vaqta).

Through the dual-wheel driving pattern characterized by “R&D + Marketing”, Zhifei has formed a good cycle mechanism which succeeds in realizing the mutual facilitation and mutual transformation between R&D and marketing, accelerating the commercialization process of vaccine products and gradually forming its core competitiveness which is uniquely characteristic and leads the market.

Zhifei has built up an R&D team composed of experts with outstanding quality and always attaches importance to the introduction and development of technology. Zhifei has successively participated in over 20 major projects such as 863 High-Tech Program entitled "Modern Medical Technology", “Major New Drugs Innovation and Development” under Ministry of Science and Technology and other state's major projects. The Company has two R&D bases, one R&D center and twenty-eight ongoing projects including those that are in the process of applying for market approval, those that have received clinical permits and those in pre-clinical stages, which mainly involve the vaccines for human use such as those for the prevention of meningitis, tuberculosis, pneumonia, flu, rabies and norovirus infection, and the R&D products portfolio has rich hierarchy. The Company’s Recombinant Mycobacterium Tuberculosis Fusion Protein (EC) (product name: Ekear®) was granted the certificate for national Category 1 new drug and the production license number by the National Medical Products Administration on April 28, 2020. The product is the first of its kink in China and will solve the problem related to tuberculin products (PPD, etc.) which have been used for a hundred of years but cannot distinguish BCG vaccination from tuberculosis infection.Meanwhile, to further extend its business scope and scale, Zhifei began to make strategic arrangement, entering into the industry of therapeutic biological products.

In addition, Zhifei has constructed its in-depth service network with comprehensive coverage, which supplies sustainable, rapid and all-sided first-rate service for more than 30,000 points of vaccination (POVs) (township POVs and community outpatient clinics) of over 2,600 districts or counties in more than 300 cities of 31 provinces, autonomous regions and municipalities directly under the Central Government across the country. At the same time, by self-building its cold chain system conforming to national GSP requirements, Zhifei has realized a seamless cold chain with regard to the storage and transportation of vaccines. Through the real time temperature monitoring system, vaccine products can be transported to various county-level CDCs safely and soundly by refrigerated vehicles that can realize long-distance automation monitoring and alarm.

Since its establishment, Zhifei has always adhered to the business philosophy of "Social benefits go before corporate profits" and its core value featuring "six firsts and six seconds". Aiming at enhancing people’s awareness of disease prevention as its mission, Zhifei has successively rolled out over ten vaccines against various diseases on the market, promoting the development of public health and creating good social benefits. Zhifei’s accumulated tax payment has reached over RMB3.4 billion, functioning to promote the development of public health and create better social benefits. In addition, the Company regards social welfare as a key channel to repay the society and assume social responsibility. In 2020 when the COVID-19 pandemic just broke out, the Company took initiative to donate RMB10 million to Hubei Province for pandemic control. The Company always attaches great importance to the development of grass-roots health care and educational causes.  Zhifei has successively donated money to the Escort Disease Control Fund of China Population Welfare Foundation, China Women’s Development Foundation, Chongqing Charity Association, China Red Cross Foundation, rural schools, university libraries and so forth to support disease prevention and women’s health, improve the conditions of primary health care institutions, upgrade school facilities, and subsidize rural poverty-stricken students and needy children influenced by AIDS to receive education and treatment.

On the strength of its unremitting development for over a decade, Zhifei has been well recognized by all walks of life and won honorary titles such as one of Top 100 CPC Party Organizations of non-public enterprises that are strong both in Party building and development, Chongqing Role Model in Ethical and Cultural Progress, National Level Enterprises of Observing Contract & Valuing Credit, National Pilot Enterprise in Business Integrity, Innovative Enterprise in Chongqing ,Top 100 Manufacturing Enterprises in Chongqing, Top 20 Best A-share Listed Companies awarded at China Capital Annual Meeting 2019, Top 100 Chinese Pharmaceutical Enterprises in 2018 awarded by All-China Federation of Industry and Commerce Medical & Pharmaceutical Industry Chamber and China’s AAA-level Credit Enterprise.